Decreased PEMT Gene Expression In The Liver Is Linked To Severity In Nonalcoholic Fatty Liver Disease

PHOENIX, Ariz. — August 22, 2022 — Nonalcoholic fatty liver disease (NAFLD) is both increasingly common and potentially deadly; yet its causes remain poorly understood. Now, a collaborative team of researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, and Temple University has uncovered a link between decreases in an enzyme that makes choline in the liver —an essential nutrient for humans— and severity of NAFLD.

Continue reading

Arizona Commerce Authority offering a registration reimbursement grant for TechConnect Conference 2022

TechConnect is the premier SBIR conference where companies across the country gather to hear from experts and connect directly with SBIR program managers. Many companies credit the experience and knowledge they gained from attending with helping them submit a successful SBIR application.

The Arizona Commerce Authority understands that the cost of travel and accommodations may not be feasible for everyone, so they are offering a registration reimbursement grant to AZBio members. 

Continue reading

Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

Preclinical prostate cancer (PCa] studies published in the December 17th, 2021 issue of Pharmaceuticals show Aqualung Therapeutic’s ALT-100 mAb to significantly improve overall survival and to reduce distal metastases in SCID mice implanted with human prostate cancer (PCa] cells. Aqualung Therapeutics is an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform to address life-threatening unchecked inflammation.

Continue reading